{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T17:47:29Z","timestamp":1755798449873,"version":"3.44.0"},"reference-count":51,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100018558","name":"Shanghai Shuguang Program","doi-asserted-by":"publisher","award":["23SG33"],"award-info":[{"award-number":["23SG33"]}],"id":[{"id":"10.13039\/501100018558","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Thyroid-associated ophthalmopathy (TAO), also known as Graves\u2019 ophthalmopathy (GO) is an autoimmune disease (AD) with abnormal thyroid function typically. Currently, intravenous glucocorticoid therapy remains the first-line treatment for moderate-to-severe active TAO. Second-line treatments, including immunosuppressants and biological agents, are being explored in depth. However, like other ADs, the adverse effects of these therapies, little impact on long-term sequelae, and the irreversible progression of the disease remain significant limitations. As a result, the development of new therapeutic strategies for TAO is essential. Chimeric antigen receptors (CAR)-based adoptive cell therapy has emerged as an innovative approach for ADs treatment, capitalizing on its principles of genetically modifying immune cells to specifically target pathogenic cells. This approach aims to reduce autoimmune response or eliminate effective cells, CAR-based therapies of both T-cell-mediated and B-cell-mediated ADs have shown promising results in wide clinical trial. CAR-based therapy obviously become a rising star on refractory and relapsed ADs. TAO is no exception in terms of the potential for improvement through CAR-based therapy. However, the success of CAR-based therapy in TAO depends critically on identifying appropriate targets. Selected targets need to be coverage to ensure the therapeutic efficiency while specificity to preserve safety. Furthermore, the target cells must be relevant to the pathogenesis of TAO. Except target selection, adopting advanced and effective strategies for CAR design is also crucial. For example, dual-target approaches involving thyroid-stimulating hormone receptor (TSHR) or insulin-like growth factor-1 receptor (lGF-1R), off-the-shelf CAR-based cells, or leveraging artificial intelligence (Al) to predict optimal targets could enhance the specificity and effectiveness of CAR-based, therapies in TAO treatment.<\/jats:p>","DOI":"10.1515\/mr-2024-0099","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T07:57:56Z","timestamp":1744358276000},"page":"339-347","source":"Crossref","is-referenced-by-count":0,"title":["Can chimeric antigen receptors\u00a0\u2013 based therapy bring a gleam of hope for thyroid-associated ophthalmopathy and other autoimmune diseases?"],"prefix":"10.1515","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1001-6300","authenticated-orcid":false,"given":"Weiyi","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Endocrinology , 56652 Changzheng Hospital, Naval Medical University , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology , 56652 Changzheng Hospital, Naval Medical University , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongquan","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology , 56652 Changzheng Hospital, Naval Medical University , Shanghai , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"2025081907580747394_j_mr-2024-0099_ref_001","doi-asserted-by":"crossref","unstructured":"Hoang, TD, Stocker, DJ, Chou, EL, Burch, HB. 2022 Update on clinical management of graves disease and thyroid eye disease. Endocrinol Metab Clin North Am. 2022;51:287\u2013304, https:\/\/doi.org\/10.1016\/j.ecl.2021.12.004.","DOI":"10.1016\/j.ecl.2021.12.004"},{"key":"2025081907580747394_j_mr-2024-0099_ref_002","doi-asserted-by":"crossref","unstructured":"Bartalena, L, Gallo, D, Tanda, ML, Kahaly, GJ. Thyroid eye disease: epidemiology, natural history, and risk factors. Ophthalmic Plast Reconstr Surg 2023;39:S2\u20138. https:\/\/doi.org\/10.1097\/iop.0000000000002467.","DOI":"10.1097\/IOP.0000000000002467"},{"key":"2025081907580747394_j_mr-2024-0099_ref_003","doi-asserted-by":"crossref","unstructured":"Smith, TJ, Heged\u00fcs, L. Graves\u2019 disease. N Engl J Med 2016;375:1552\u201365. https:\/\/doi.org\/10.1056\/nejmra1510030.","DOI":"10.1056\/NEJMra1510030"},{"key":"2025081907580747394_j_mr-2024-0099_ref_004","doi-asserted-by":"crossref","unstructured":"Smith, TJ. Understanding pathogenesis intersects with effective treatment for thyroid eye disease. J Clin Endocrinol Metab 2022;107:S13\u201326. https:\/\/doi.org\/10.1210\/clinem\/dgac328.","DOI":"10.1210\/clinem\/dgac328"},{"key":"2025081907580747394_j_mr-2024-0099_ref_005","doi-asserted-by":"crossref","unstructured":"Khong, JJ, Finch, S, De Silva, C, Rylander, S, Craig, JE, Selva, D, et al.. Risk factors for graves\u2019 orbitopathy; the Australian thyroid-associated orbitopathy research (ATOR) study. J Clin Endocrinol Metab. 2016;101:2711\u201320, https:\/\/doi.org\/10.1210\/jc.2015-4294.","DOI":"10.1210\/jc.2015-4294"},{"key":"2025081907580747394_j_mr-2024-0099_ref_006","unstructured":"Bartley, GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994;92:477\u2013588."},{"key":"2025081907580747394_j_mr-2024-0099_ref_007","unstructured":"Schovanek, J, Radvansky, M, Karhanova, M, Bolacka, M, Pekarova, K, Dohnal, R, et al.. Long-term impact of thyroid eye disease on quality of life: insights from a retrospective cohort study. Endocr Pract. 2025;S1530-891X:0004-2."},{"key":"2025081907580747394_j_mr-2024-0099_ref_008","doi-asserted-by":"crossref","unstructured":"Wang, C, Qiao, J, Liu, S, Piao, S, Zhou, Y, Hu, Y, et al.. Selenium in the treatment of mild-to-moderate Graves\u2019 orbitopathy: a 5-year prospective controlled cohort study. Endocrine 2024;84:1072\u201380. https:\/\/doi.org\/10.1007\/s12020-023-03672-5.","DOI":"10.1007\/s12020-023-03672-5"},{"key":"2025081907580747394_j_mr-2024-0099_ref_009","doi-asserted-by":"crossref","unstructured":"Ponto, KA, Merkesdal, S, Hommel, G, Pitz, S, Pfeiffer, N, Kahaly, GJ. Public health relevance of Graves\u2019 orbitopathy. J Clin Endocrinol Metab 2013;98:145\u201352. https:\/\/doi.org\/10.1210\/jc.2012-3119.","DOI":"10.1210\/jc.2012-3119"},{"key":"2025081907580747394_j_mr-2024-0099_ref_010","doi-asserted-by":"crossref","unstructured":"Zang, S, Ponto, KA, Kahaly, GJ. Clinical review: intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 2011;96:320\u201332. https:\/\/doi.org\/10.1210\/jc.2010-1962.","DOI":"10.1210\/jc.2010-1962"},{"key":"2025081907580747394_j_mr-2024-0099_ref_011","doi-asserted-by":"crossref","unstructured":"Bartalena, L, Krassas, GE, Wiersinga, W, Marcocci, C, Salvi, M, Daumerie, C, et al.. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy. J Clin Endocrinol Metab 2012;97:4454\u201363. https:\/\/doi.org\/10.1210\/jc.2012-2389.","DOI":"10.1210\/jc.2012-2389"},{"key":"2025081907580747394_j_mr-2024-0099_ref_012","doi-asserted-by":"crossref","unstructured":"Wiersinga, WM. Immunosuppressive treatment of Graves\u2019 ophthalmopathy. Trends Endocrinol Metab 1990;1:377\u201381. https:\/\/doi.org\/10.1016\/1043-2760(90)90095-k.","DOI":"10.1016\/1043-2760(90)90095-K"},{"key":"2025081907580747394_j_mr-2024-0099_ref_013","doi-asserted-by":"crossref","unstructured":"Marin\u00f3, M, Morabito, E, Brunetto, MR, Bartalena, L, Pinchera, A, Marocci, C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves\u2019 ophthalmopathy. Thyroid 2004;14:403\u20136. https:\/\/doi.org\/10.1089\/105072504774193276.","DOI":"10.1089\/105072504774193276"},{"key":"2025081907580747394_j_mr-2024-0099_ref_014","doi-asserted-by":"crossref","unstructured":"L\u00e4ngericht, J, Kr\u00e4mer, I, Kahaly, GJ. Glucocorticoids in Graves\u2019 orbitopathy: mechanisms of action and clinical application. Ther Adv Endocrinol Metab 2020;11. https:\/\/doi.org\/10.1177\/2042018820958335.","DOI":"10.1177\/2042018820958335"},{"key":"2025081907580747394_j_mr-2024-0099_ref_015","doi-asserted-by":"crossref","unstructured":"Prummel, MF, Mourits, MP, Berghout, A, Krenning, EP, van der Gaag, R, Koornneef, L, et al.. Prednisone and cyclosporine in the treatment of severe Graves\u2019 ophthalmopathy. N Engl J Med 1989;321:1353\u20139. https:\/\/doi.org\/10.1056\/nejm198911163212002.","DOI":"10.1056\/NEJM198911163212002"},{"key":"2025081907580747394_j_mr-2024-0099_ref_016","doi-asserted-by":"crossref","unstructured":"Perros, P, Weightman, DR, Crombie, AL, Kendall-Taylor, P. Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol (Copenh) 1990;122:8\u201312. https:\/\/doi.org\/10.1530\/acta.0.1220008.","DOI":"10.1530\/acta.0.1220008"},{"key":"2025081907580747394_j_mr-2024-0099_ref_017","doi-asserted-by":"crossref","unstructured":"Chalvatzis, NT, Tzamalis, AK, Kalantzis, GK, El-Hindy, N, Dimitrakos, SA, Potts, MJ. Safety and efficacy of combined immunosuppression and orbital radiotherapy in thyroid-related restrictive myopathy: two-center experience. Eur J Ophthalmol 2014;24:953\u20139. https:\/\/doi.org\/10.5301\/ejo.5000463.","DOI":"10.5301\/ejo.5000463"},{"key":"2025081907580747394_j_mr-2024-0099_ref_018","doi-asserted-by":"crossref","unstructured":"Sipkova, Z, Insull, EA, David, J, Turner, HE, Keren, S, Norris, JH. Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease: a step-down approach. Clin Endocrinol (Oxf) 2018;89:834\u20139. https:\/\/doi.org\/10.1111\/cen.13834.","DOI":"10.1111\/cen.13834"},{"key":"2025081907580747394_j_mr-2024-0099_ref_019","doi-asserted-by":"crossref","unstructured":"Xiang, Q, Yang, M, Luo, W, Cao, Y, Shuai, S, Wei, X, et al.. Combined glucocorticoids and cyclophosphamide in the treatment of Graves\u2019 ophthalmopathy: a systematic review and meta-analysis. BMC Endocr Disord 2024;24:12. https:\/\/doi.org\/10.1186\/s12902-024-01545-0.","DOI":"10.1186\/s12902-024-01545-0"},{"key":"2025081907580747394_j_mr-2024-0099_ref_020","doi-asserted-by":"crossref","unstructured":"Azzola, A, Havryk, A, Chhajed, P, Hostettler, K, Black, J, Johnson, P, et al.. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. Transplantation 2004;77:275\u201380. https:\/\/doi.org\/10.1097\/01.tp.0000101822.50960.ab.","DOI":"10.1097\/01.TP.0000101822.50960.AB"},{"key":"2025081907580747394_j_mr-2024-0099_ref_021","doi-asserted-by":"crossref","unstructured":"Kahaly, GJ, Riedl, M, K\u00f6nig, J, Pitz, S, Ponto, K, Diana, T, et al.. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol 2018;6:287\u201398. https:\/\/doi.org\/10.1016\/s2213-8587(18)30020-2.","DOI":"10.1016\/S2213-8587(18)30020-2"},{"key":"2025081907580747394_j_mr-2024-0099_ref_022","doi-asserted-by":"crossref","unstructured":"Feng, W, Hu, Y, Zhang, C, Shi, H, Zhang, P, Yang, Y, et al.. Efficacy and safety of mycophenolate mofetil in the treatment of moderate to severe Graves\u2019 orbitopathy: a meta-analysis. Bioengineered 2022;13:14719\u201329. https:\/\/doi.org\/10.1080\/21655979.2022.2101191.","DOI":"10.1080\/21655979.2022.2101191"},{"key":"2025081907580747394_j_mr-2024-0099_ref_023","doi-asserted-by":"crossref","unstructured":"Shams, PN, Ma, R, Pickles, T, Rootman, J, Dolman, PJ. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol 2014;157:1299\u2013305. https:\/\/doi.org\/10.1016\/j.ajo.2014.02.044.","DOI":"10.1016\/j.ajo.2014.02.044"},{"key":"2025081907580747394_j_mr-2024-0099_ref_024","doi-asserted-by":"crossref","unstructured":"Choi, JH, Lee, JK. Efficacy of orbital radiotherapy in moderate-to-severe active graves\u2019 orbitopathy including long-lasting disease: a retrospective analysis. Radiat Oncol 2020;15:220. https:\/\/doi.org\/10.1186\/s13014-020-01663-8.","DOI":"10.1186\/s13014-020-01663-8"},{"key":"2025081907580747394_j_mr-2024-0099_ref_025","doi-asserted-by":"crossref","unstructured":"Hahn, E, Laperriere, N, Millar, BA, Oestreicher, J, McGowan, H, Krema, H, et al.. Orbital radiation therapy for Graves\u2019 ophthalmopathy: measuring clinical efficacy and impact. Pract Radiat Oncol 2014;4:233\u20139. https:\/\/doi.org\/10.1016\/j.prro.2014.02.008.","DOI":"10.1016\/j.prro.2014.02.008"},{"key":"2025081907580747394_j_mr-2024-0099_ref_026","doi-asserted-by":"crossref","unstructured":"Bradley, EA, Gower, EW, Bradley, DJ, Meyer, DR, Cahill, KV, Custer, PL, et al.. Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2008;115:398\u2013409. https:\/\/doi.org\/10.1016\/j.ophtha.2007.10.028.","DOI":"10.1016\/j.ophtha.2007.10.028"},{"key":"2025081907580747394_j_mr-2024-0099_ref_027","doi-asserted-by":"crossref","unstructured":"Douglas, RS, Kahaly, GJ, Patel, A, Sile, S, Thompson, EHZ, Perdok, R, et al.. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 2020;382:341\u201352. https:\/\/doi.org\/10.1056\/nejmoa1910434.","DOI":"10.1056\/NEJMoa1910434"},{"key":"2025081907580747394_j_mr-2024-0099_ref_028","doi-asserted-by":"crossref","unstructured":"Douglas, RS, Kahaly, GJ, Ugradar, S, Elflein, H, Ponto, KA, Fowler, BT, et al.. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and Re-treatment: OPTIC-X study. Ophthalmology 2022;129:438\u201349. https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.017.","DOI":"10.1016\/j.ophtha.2021.10.017"},{"key":"2025081907580747394_j_mr-2024-0099_ref_029","doi-asserted-by":"crossref","unstructured":"Kahaly, GJ, Douglas, RS, Holt, RJ, Sile, S, Smith, TJ. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol 2021;9:360\u201372. https:\/\/doi.org\/10.1016\/s2213-8587(21)00056-5.","DOI":"10.1016\/S2213-8587(21)00056-5"},{"key":"2025081907580747394_j_mr-2024-0099_ref_030","doi-asserted-by":"crossref","unstructured":"Douglas, RS, Couch, S, Wester, ST, Fowler, BT, Liu, CY, Subramanian, PS, et al.. Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab 2023;109:25\u201335. https:\/\/doi.org\/10.1210\/clinem\/dgad637.","DOI":"10.1210\/clinem\/dgad637"},{"key":"2025081907580747394_j_mr-2024-0099_ref_031","doi-asserted-by":"crossref","unstructured":"Wong, PC, Christ, DD, Timmermans, PB. Enhancement of losartan (DuP 753)-induced angiotensin II receptor antagonism by PD123177 in rats. Eur J Pharmacol 1992;220:267\u201370. https:\/\/doi.org\/10.1016\/0014-2999(92)90758-v.","DOI":"10.1016\/0014-2999(92)90758-V"},{"key":"2025081907580747394_j_mr-2024-0099_ref_032","doi-asserted-by":"crossref","unstructured":"Gulbins, A, Horstmann, M, Daser, A, Fl\u00f6gel, U, Oeverhaus, M, Bechrakis, NE, et al.. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease. Front Endocrinol (Lausanne) 2023;14:1211473. https:\/\/doi.org\/10.3389\/fendo.2023.1211473.","DOI":"10.3389\/fendo.2023.1211473"},{"key":"2025081907580747394_j_mr-2024-0099_ref_033","doi-asserted-by":"crossref","unstructured":"Salvi, M, Vannucchi, G, Curr\u00f2, N, Campi, I, Covelli, D, Dazzi, D, et al.. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 2015;100:422\u201331. https:\/\/doi.org\/10.1210\/jc.2014-3014.","DOI":"10.1210\/jc.2014-3014"},{"key":"2025081907580747394_j_mr-2024-0099_ref_034","doi-asserted-by":"crossref","unstructured":"Chen, J, Chen, G, Sun, H. Intravenous rituximab therapy for active Graves\u2019 ophthalmopathy: a meta-analysis. Hormones (Athens) 2021;20:279\u201386. https:\/\/doi.org\/10.1007\/s42000-021-00282-6.","DOI":"10.1007\/s42000-021-00282-6"},{"key":"2025081907580747394_j_mr-2024-0099_ref_035","doi-asserted-by":"crossref","unstructured":"Shen, WC, Lee, CH, Loh, EW, Hsieh, AT, Chen, L, Tam, KW. Efficacy and safety of rituximab for the treatment of Graves\u2019 orbitopathy: a meta-analysis of randomized controlled trials. Pharmacotherapy 2018;38:503\u201310. https:\/\/doi.org\/10.1002\/phar.2111.","DOI":"10.1002\/phar.2111"},{"key":"2025081907580747394_j_mr-2024-0099_ref_036","doi-asserted-by":"crossref","unstructured":"Kang, S, Hamed Azzam, S, Minakaran, N, Ezra, DG. Rituximab for thyroid-associated ophthalmopathy. Cochrane Database Syst Rev 2022;6:CD009226. https:\/\/doi.org\/10.1002\/14651858.CD009226.pub3.","DOI":"10.1002\/14651858.CD009226.pub3"},{"key":"2025081907580747394_j_mr-2024-0099_ref_037","doi-asserted-by":"crossref","unstructured":"Perez-Moreiras, JV, Gomez-Reino, JJ, Maneiro, JR, Perez-Pampin, E, Romo Lopez, A, Rodr\u00edguez Alvarez, FM, et al.. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial. Am J Ophthalmol 2018;195:181\u201390. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.038.","DOI":"10.1016\/j.ajo.2018.07.038"},{"key":"2025081907580747394_j_mr-2024-0099_ref_038","doi-asserted-by":"crossref","unstructured":"Molina-Molina, M, Machahua-Huamani, C, Vicens-Zygmunt, V, Llatj\u00f3s, R, Escobar, I, Sala-Llinas, E, et al.. Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. BMC Pulm Med 2018;18:63. https:\/\/doi.org\/10.1186\/s12890-018-0626-4.","DOI":"10.1186\/s12890-018-0626-4"},{"key":"2025081907580747394_j_mr-2024-0099_ref_039","doi-asserted-by":"crossref","unstructured":"Zhang, L, Grennan-Jones, F, Lane, C, Rees, DA, Dayan, CM, Ludgate, M. Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to Graves\u2019 orbitopathy. J Clin Endocrinol Metab 2012;97:653\u201362. https:\/\/doi.org\/10.1210\/jc.2011-1299.","DOI":"10.1210\/jc.2011-1299"},{"key":"2025081907580747394_j_mr-2024-0099_ref_040","doi-asserted-by":"crossref","unstructured":"Roos, JCP, Murthy, R. Sirolimus (rapamycin) for the targeted treatment of the fibrotic sequelae of Graves\u2019 orbitopathy. Eye (Lond). 2019;33:679\u201382. https:\/\/doi.org\/10.1038\/s41433-019-0340-3.","DOI":"10.1038\/s41433-019-0340-3"},{"key":"2025081907580747394_j_mr-2024-0099_ref_041","doi-asserted-by":"crossref","unstructured":"Lanzolla, G, Maglionico, MN, Comi, S, Menconi, F, Piaggi, P, Posarelli, C, et al.. Sirolimus as a second-line treatment for Graves\u2019 orbitopathy. J Endocrinol Invest 2022;45:2171\u201380. https:\/\/doi.org\/10.1007\/s40618-022-01862-y.","DOI":"10.1007\/s40618-022-01862-y"},{"key":"2025081907580747394_j_mr-2024-0099_ref_042","doi-asserted-by":"crossref","unstructured":"Kahaly, GJ, Dolman, PJ, Wolf, J, Giers, BC, Elflein, HM, Jain, AP, et al.. Proof-of-concept and randomized, placebo-controlled trials of an FcRn inhibitor, batoclimab, for thyroid eye disease. J Clin Endocrinol Metab 2023;108:3122\u201334. https:\/\/doi.org\/10.1210\/clinem\/dgad381.","DOI":"10.1210\/clinem\/dgad381"},{"key":"2025081907580747394_j_mr-2024-0099_ref_043","doi-asserted-by":"crossref","unstructured":"Cheever, A, Kang, CC, O\u2019Neill, KL, Weber, KS. Application of novel CAR technologies to improve treatment of autoimmune disease. Front Immunol 2024;15:1465191. https:\/\/doi.org\/10.3389\/fimmu.2024.1465191.","DOI":"10.3389\/fimmu.2024.1465191"},{"key":"2025081907580747394_j_mr-2024-0099_ref_044","doi-asserted-by":"crossref","unstructured":"Fishman, S, Lewis, MD, Siew, LK, De Leenheer, E, Kakabadse, D, Davies, J, et al.. Adoptive transfer of mRNA-transfected T\u00a0cells redirected against diabetogenic CD8 T\u00a0cells can prevent diabetes. Mol Ther 2017;25:456\u201364. https:\/\/doi.org\/10.1016\/j.ymthe.2016.12.007.","DOI":"10.1016\/j.ymthe.2016.12.007"},{"key":"2025081907580747394_j_mr-2024-0099_ref_045","doi-asserted-by":"crossref","unstructured":"Wei, J, Han, X, Bo, J, Han, W. Target selection for CAR-T therapy. J Hematol Oncol 2019;12:62. https:\/\/doi.org\/10.1186\/s13045-019-0758-x.","DOI":"10.1186\/s13045-019-0758-x"},{"key":"2025081907580747394_j_mr-2024-0099_ref_046","doi-asserted-by":"crossref","unstructured":"Bahn, RS. Graves\u2019 ophthalmopathy. N Engl J Med 2010;362:726\u201338. https:\/\/doi.org\/10.1056\/nejmra0905750.","DOI":"10.1056\/NEJMra0905750"},{"key":"2025081907580747394_j_mr-2024-0099_ref_047","unstructured":"Wang, X, Wu, X, Tan, B, Zhu, L, Zhang, Y, Lin, L, et al.. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell 2024;S0092\u20138674:00701\u20133."},{"key":"2025081907580747394_j_mr-2024-0099_ref_048","unstructured":"TSHR-based chimeric antigen receptor T\u00a0cell specifically deplete auto-reactive B lymphocytes for treatment of autoimmune thyroid disease - PubMed [Internet]. [cited 2025 Feb 17]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37690235\/."},{"key":"2025081907580747394_j_mr-2024-0099_ref_049","doi-asserted-by":"crossref","unstructured":"Ding, J, Li, D, Liu, X, Hei, H, Sun, B, Zhou, D, et al.. Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer. Exp Hematol Oncol 2022;11:59. https:\/\/doi.org\/10.1186\/s40164-022-00311-z.","DOI":"10.1186\/s40164-022-00311-z"},{"key":"2025081907580747394_j_mr-2024-0099_ref_050","doi-asserted-by":"crossref","unstructured":"Zhou, J, Zhang, C, Mao, W, Zhu, Y, Zhao, H, Han, R, et al.. Development of TSHR-CAR NK-92 cells for differentiated thyroid cancer. Mol Cell Endocrinol 2024;589:112251. https:\/\/doi.org\/10.1016\/j.mce.2024.112251.","DOI":"10.1016\/j.mce.2024.112251"},{"key":"2025081907580747394_j_mr-2024-0099_ref_051","unstructured":"IGF1R- and ROR1-specific CAR T\u00a0cells as a potential therapy for high risk sarcomas - PubMed [Internet]. [cited 2025 Feb 17]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26173023\/."}],"container-title":["Medical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/mr-2024-0099\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/mr-2024-0099\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T07:59:25Z","timestamp":1755590365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/mr-2024-0099\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,28]]},"published-print":{"date-parts":[[2025,8,20]]}},"alternative-id":["10.1515\/mr-2024-0099"],"URL":"https:\/\/doi.org\/10.1515\/mr-2024-0099","relation":{},"ISSN":["2749-9642"],"issn-type":[{"type":"electronic","value":"2749-9642"}],"subject":[],"published":{"date-parts":[[2025,4,14]]}}}